Evoke plc (LON:EVOK – Get Free Report)’s stock price fell 10% on Thursday . The stock traded as low as GBX 50.20 ($0.65) and last traded at GBX 51.73 ($0.67). 65,066,164 shares changed hands during mid-day trading, an increase of 1,994% from the average session volume of 3,107,171 shares. The stock had previously closed at GBX 57.45 ($0.74).
Analysts Set New Price Targets
EVOK has been the subject of several recent analyst reports. Berenberg Bank cut their price objective on Evoke from GBX 130 ($1.68) to GBX 90 ($1.16) and set a “buy” rating for the company in a report on Wednesday, December 4th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 140 ($1.81) price target on shares of Evoke in a research note on Monday, December 16th.
View Our Latest Analysis on Evoke
Evoke Stock Down 1.1 %
Evoke (LON:EVOK – Get Free Report) last announced its quarterly earnings data on Wednesday, March 26th. The company reported GBX (6.40) (($0.08)) earnings per share for the quarter. Evoke had a negative net margin of 8.50% and a negative return on equity of 517.98%. Research analysts expect that Evoke plc will post 12.7648305 earnings per share for the current year.
Insider Transactions at Evoke
In related news, insider Andrea Gisle Joosen acquired 14,572 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The shares were purchased at an average price of GBX 70 ($0.91) per share, for a total transaction of £10,200.40 ($13,202.69). Company insiders own 27.00% of the company’s stock.
About Evoke
Recommended Stories
- Five stocks we like better than Evoke
- Airline Stocks – Top Airline Stocks to Buy Now
- MarketBeat Week in Review – 03/24 – 03/28
- What Are Dividend Champions? How to Invest in the Champions
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- How to Short Nasdaq: An Easy-to-Follow Guide
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Evoke Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke and related companies with MarketBeat.com's FREE daily email newsletter.